The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.
Khurum Hayat Khan
No relevant relationships to disclose
Clare Peckitt
No relevant relationships to disclose
Francesco Sclafani
No relevant relationships to disclose
Sachin Trivedi
No relevant relationships to disclose
Vikram Kumar Jain
No relevant relationships to disclose
Susannah Jane Stanway
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Ian Chau
Consultant or Advisory Role - Merck Serono (U); Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Merck Serono; Roche